Challenges faced by patients with dyslipidemia and systemic arterial hypertension in Brazil: a design of the patient journey.

Autor: Faria-Neto JR; School of Medicine, Pontificial Catholic University of Parana (PUCPR), Curitiba, Brazil., Yarleque C; Research, Development and Medical, Upjohn - A Division of Pfizer, Lima, Peru., Vieira LF; Research, Development and Medical, Pfizer Upjohn, Sao Paulo, Brazil., Sakane EN; Research, Development and Medical, Pfizer Upjohn, Sao Paulo, Brazil., Santos RD; Heart Institute (InCor) University of Sao Paulo Medical School Hospital, São Paulo, Brazil. raul.santos@incor.usp.br.; Academic Research Organization, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. raul.santos@incor.usp.br.
Jazyk: angličtina
Zdroj: BMC cardiovascular disorders [BMC Cardiovasc Disord] 2022 May 21; Vol. 22 (1), pp. 237. Date of Electronic Publication: 2022 May 21.
DOI: 10.1186/s12872-022-02669-8
Abstrakt: Background and Objective: Non-communicable diseases like systemic arterial hypertension (SAH) and dyslipidemia are poorly studied in terms of patient journey aspects. This semi-systematic review provides evidence synthesis for the management of SAH and dyslipidemia in Brazil and also discusses challenges faced by patients at the local level along with a suggested care approach by local experts.
Methods: A semi-systematic review using both structured literature databases (Embase and Medline) and unstructured scientific records (WHO, IPD, MOH and Google) on hypertension and dyslipidemia in the English language from 2010 to 2019 was performed by reviewers. After two-level screening based on pre-defined criteria, patient journey touchpoints and prevalence information were extracted from the included articles. Data gaps were bridged through the insights of local experts.
Results: Prevalence of hypertension and dyslipidemia in Brazil were 23% and 40.8%, respectively. Awareness of dyslipidemia was found in a larger proportion (58.1%) than in SAH (22.2%). Similarly, screening for hypertension (97%) and dyslipidemia (55.4%) were found to be effective, while treatment was (62.9%) and (30.0%) for hypertension and dyslipidemia, respectively.
Conclusion: There were important gaps on patient awareness and treatment of dyslipidemia and hypertension. Limited patient education, regional disease distribution, and treatment allocation, along with limited resources for diagnosis and treatment are the key challenges.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: